$3.32
7.10% yesterday
Nasdaq, May 20, 09:49 pm CET
ISIN
IL0011839383
Symbol
DRTS
Sector

Alpha Tau Medical Stock price

$3.26
+0.62 23.48% 1M
+0.97 42.05% 6M
+0.16 5.16% YTD
+0.55 20.30% 1Y
-2.15 39.74% 3Y
-6.84 67.72% 5Y
-6.84 67.72% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.16 5.16%
ISIN
IL0011839383
Symbol
DRTS
Sector

Key metrics

Market capitalization $275.44m
Enterprise Value $232.88m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 4.08
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-36.93m
Cash position $54.85m
EPS (TTM) EPS $-0.46
P/S forward 847.51
EV/Sales forward 716.55
Short interest 0.15%
Show more

Is Alpha Tau Medical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Alpha Tau Medical Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Alpha Tau Medical forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Alpha Tau Medical forecast:

Buy
100%

Financial data from Alpha Tau Medical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.18 9.18
26% 26%
-
- Research and Development Expense 28 28
4% 4%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -37 -37
4% 4%
-
Net Profit -32 -32
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alpha Tau Medical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alpha Tau Medical Stock News

Neutral
GlobeNewsWire
one day ago
- Interim Jan-2025 results from three trials of Alpha DaRT ® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate , impressive overall survival in sub-group analys e s, and positive safety profile -
Neutral
GlobeNewsWire
8 days ago
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq:  DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company's Board of Directors (“Board”). Th...

Company Profile

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Uzi Sofer
Employees 112
Founded 2015
Website www.alphatau.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today